| The risks and benefits of aldosterone antagonists. | |
| | |
MedLine Citation:
|
PMID: 16036053 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Spironolactone and eplerenone are mineralocorticoid- blocking agents used for their ability to block a host of epithelial and nonepithelial actions of aldosterone. These compounds are of proven benefit in reducing blood pressure and urine protein excretion, and in conferring cardiovascular gain in diverse circumstances of heart failure. However, as enthusiasm grows for use of mineralocorticoid-blocking agents, the risks inherent to use of such drugs become more pertinent. Whereas the endocrine side effects of spironolactone are in reality little more than a cosmetic disfigurement, the potassium-sparing properties of spironolactone and eplerenone can prove life-threatening if hyperkalemia develops. However, for most patients the risk of developing hyperkalemia should not dissuade the prudent clinician from use of these compounds. Hyperkalemia should be considered as a possibility in any patient receiving these medications and as such is best addressed preemptively. |
| | |
Authors:
|
Domenic A Sica |
Related Documents
:
|
14985063 - Review of aldosterone- and angiotensin ii-induced target organ damage and prevention. 3890393 - Is the antihypertensive effect of muzolimine due to volume depletion? 19735743 - Elastic incoherent neutron scattering as a probe of high pressure induced changes in pr... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current heart failure reports Volume: 2 ISSN: 1546-9530 ISO Abbreviation: Curr Heart Fail Rep Publication Date: 2005 Aug |
Date Detail:
|
Created Date: 2005-07-22 Completed Date: 2005-09-01 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 101196487 Medline TA: Curr Heart Fail Rep Country: United States |
Other Details:
|
Languages: eng Pagination: 65-71 Citation Subset: IM |
Affiliation:
|
Division of Nephrology, Box 980160, MCV Station, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23298, USA. dsica@hsc.vcu.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aldosterone Antagonists
/
adverse effects,
therapeutic use* Heart Failure / drug therapy* Humans Hyperkalemia / chemically induced Spironolactone / adverse effects, analogs & derivatives*, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Aldosterone Antagonists; 0/eplerenone; 52-01-7/Spironolactone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The addition of angiotensin receptor blockers to angiotensin-converting enzyme inhibitors--what has ...
Next Document: The impact of race on response to RAAS inhibition.